blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2638041

EP2638041 - SUBSTITUTED AZAINDAZOLE COMPOUNDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.05.2016
Database last updated on 02.11.2024
Most recent event   Tooltip19.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 21.11.2018  [2018/47]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2015/30]
Former [2013/38]For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 05843-4000 / US
Inventor(s)01 / AUSTIN, Joel F.
5422 Riverside Station Boulevard
Secaucus New Jersey 07094 / US
02 / FRENNESSON, David B.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
03 / SAULNIER, Mark G.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
 [2015/30]
Former [2013/38]01 / AUSTIN, Joel F.
5422 Riverside Station Boulevard
Secaucus New Jersey 07094 / US
02 / FRENNESSON, David B.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford
Connecticut 06492 / US
03 / SAULNIER, Mark G.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford
Connecticut 06492 / US
Representative(s)Reitstötter Kinzebach
Patentanwälte
Sternwartstraße 4
81679 München / DE
[N/P]
Former [2015/30]Reitstötter Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München / DE
Former [2013/38]Reitstötter - Kinzebach
Patentanwälte Sternwartstrasse 4
81679 München / DE
Application number, filing date11785256.609.11.2011
WO2011US59914
Priority number, dateUS20100412995P12.11.2010         Original published format: US 412995 P
[2013/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012064815
Date:18.05.2012
Language:EN
[2012/20]
Type: A1 Application with search report 
No.:EP2638041
Date:18.09.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 18.05.2012 takes the place of the publication of the European patent application.
[2013/38]
Type: B1 Patent specification 
No.:EP2638041
Date:22.07.2015
Language:EN
[2015/30]
Search report(s)International search report - published on:EP18.05.2012
ClassificationIPC:C07D471/04, A61K31/437, A61P35/00
[2013/38]
CPC:
C07D471/04 (EP,US); A61P35/00 (EP); C07D487/04 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/38]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SUBSTITUIERTE AZAINDOLDERIVATE[2014/49]
English:SUBSTITUTED AZAINDAZOLE COMPOUNDS[2013/38]
French:DÉRIVÉS AZAINDOLE SUBSTITUÉS[2014/49]
Former [2013/38]SUBSTITUIERTE AZAINDAZOLVERBINDUNGEN
Former [2013/38]COMPOSÉS D'AZAINDAZOLE SUBSTITUÉS
Entry into regional phase10.06.2013National basic fee paid 
10.06.2013Designation fee(s) paid 
10.06.2013Examination fee paid 
Examination procedure10.06.2013Examination requested  [2013/38]
10.01.2014Amendment by applicant (claims and/or description)
16.04.2014Despatch of a communication from the examining division (Time limit: M04)
06.08.2014Reply to a communication from the examining division
24.11.2014Communication of intention to grant the patent
26.02.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.03.2015Communication of intention to grant the patent
10.06.2015Fee for grant paid
10.06.2015Fee for publishing/printing paid
10.06.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.04.2014
Opposition(s)25.04.2016No opposition filed within time limit [2016/26]
Fees paidRenewal fee
18.11.2013Renewal fee patent year 03
10.11.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.11.2011
AL22.07.2015
AT22.07.2015
BE22.07.2015
BG22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MK22.07.2015
MT22.07.2015
NL22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
TR22.07.2015
NO22.10.2015
GR23.10.2015
IE09.11.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
[2018/47]
Former [2018/31]HU09.11.2011
AT22.07.2015
BE22.07.2015
BG22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MK22.07.2015
MT22.07.2015
NL22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
TR22.07.2015
NO22.10.2015
GR23.10.2015
IE09.11.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
Former [2017/39]HU09.11.2011
AT22.07.2015
BE22.07.2015
BG22.07.2015
CY22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
MT22.07.2015
NL22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
SM22.07.2015
NO22.10.2015
GR23.10.2015
IE09.11.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
Former [2017/03]AT22.07.2015
BE22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IE09.11.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/45]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IE09.11.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/36]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SI22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/34]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/31]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
LU09.11.2015
IS22.11.2015
PT23.11.2015
Former [2016/28]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
MC22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/23]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RO22.07.2015
RS22.07.2015
SE22.07.2015
SK22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/22]AT22.07.2015
CZ22.07.2015
DK22.07.2015
EE22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RS22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/21]AT22.07.2015
DK22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
IT22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RS22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/20]AT22.07.2015
DK22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RS22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/11]AT22.07.2015
ES22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RS22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/10]ES22.07.2015
FI22.07.2015
HR22.07.2015
LT22.07.2015
LV22.07.2015
PL22.07.2015
RS22.07.2015
SE22.07.2015
NO22.10.2015
GR23.10.2015
IS22.11.2015
PT23.11.2015
Former [2016/09]FI22.07.2015
LT22.07.2015
LV22.07.2015
NO22.10.2015
GR23.10.2015
Former [2016/08]LT22.07.2015
NO22.10.2015
Former [2016/07]LT22.07.2015
Cited inInternational search[X]WO2010129668  (VERTEX PHARMA [US], et al) [X] 1-7 * example 1, intermediate of step 6 * * example 2, intermediates of method A, step 6 and method B, step 1 * * example 7, intermediates of method G steps 1 and 2 *;
 [XPI]WO2011004610  (TAIHO PHARMACEUTICAL CO LTD [JP], et al) [XP] 1-10 * abstract * * example - *[I] 1-10;
 [A]  - MOREIRA ET AL, "Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, (20071023), vol. 72, no. 14, doi:10.1016/J.STEROIDS.2007.08.004, ISSN 0039-128X, pages 939 - 948, XP022310307 [A] 1-10 * abstract * * figure 1 * * table 1 *

DOI:   http://dx.doi.org/10.1016/j.steroids.2007.08.004
by applicant   - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY, (1985), page 1418
    - KROGSGAARD-LARSON, P. ET AL., A Textbook of Drug Design and Development, HARWOOD ACADEMIC PUBLISHERS, (1991), pages 113 - 191
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.